Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.39 |
| ▸ | ACACA | Q13085 | 3/20 | 0.39 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | BACE1 | P56817 | 5/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.32 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12457529 | 1.00 | ACACB (0.39) | ACACBACACAANO1SLC6A3SLC6A4 | |
| SCHEMBL14689807 | 1.00 | ACACB (0.39) | ACACBACACAANO1SLC6A3SLC6A4 | |
| SCHEMBL15441421 | 0.91 | ACACB (0.45) | ACACBACACAANO1BACE1CNR1 | |
| SCHEMBL15447099 | 0.91 | ACACB (0.45) | ACACBACACAANO1BACE1CNR1 | |
| SCHEMBL2354533 | 0.91 | ANO1 (0.37) | ANO1SLC6A3SHMT1SHMT2 | |
| SCHEMBL12458145 | 0.88 | ANO1 (0.38) | ANO1SLC6A3CNR1SHMT1SHMT2 | |
| SCHEMBL2350931 | 0.88 | ANO1 (0.38) | ANO1SLC6A3CNR1SHMT1SHMT2 | |
| SCHEMBL14689724 | 0.88 | ANO1 (0.38) | ANO1SLC6A3CNR1SHMT1SHMT2 | |
| SCHEMBL2353473 | 0.87 | ANO1 (0.39) | ANO1SLC6A3SHMT1SHMT2 | |
| SCHEMBL14689906 | 0.87 | ACACB (0.40) | ACACBACACAANO1SLC6A3CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| EP-2536686-A1 | CYCLIC KETO-ENOLS FOR THERAPY | Bayer Intellectual Property GmbH (DE) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011098433-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | AKR1B1, AKR1C3, AKR1A1 | ACACB 310/4885ACACA 541/4885ANO1 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.